Fig. 3

Lenalidomide reduces microgliosis in mThy1-α-syn tg mice. a Iba1 immunostaining of the striatum of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. b Optical density quantification of Iba1 staining in the striatum. c Iba1 immunostaining of the hippocampus of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. d Optical density quantification of Iba1 staining in the hippocampus. e GFAP immunostaining of the striatum of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. f Optical density quantification of GFAP staining in the striatum. g GFAP immunostaining of the hippocampus of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. h Optical density quantification of GFAP staining in the hippocampus. Error bars represent ± SEM. *, #p < 0.05; ***p < 0.001. Scale bar = 50 μm